首页> 外文OA文献 >A Novel bispecific BCMAxCD3 T cell-engaging antibody that treat multiple myeloma (MM) with minimal cytokine secretion

【2h】

A Novel bispecific BCMAxCD3 T cell-engaging antibody that treat multiple myeloma (MM) with minimal cytokine secretion

机译：一种新的双特异性BcmaxCD3 T细胞接合抗体，其用最小的细胞因子分泌治疗多发性骨髓瘤（mm）

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Z. Li; Q. Li; G. Zhang; X. Ma; X. Hu; K. Ouyang; B. Li; Z. Liu;
展开▼
作者单位

展开▼
年度 2019
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. REGN5458, a Bispecific BCMAxCD3 T Cell Engaging Antibody, Demonstrates Robust In Vitro and In Vivo Anti-Tumor Efficacy in Multiple Myeloma Models, Comparable to That of BCMA CAR T Cells [J] . Dilillo David J., Olson Kara, Mohrs Katja, Blood: The Journal of the American Society of Hematology . 2018,第NovaelaTreatmentAppr期

机译：regn5458是一种双特异性Bcmaxcd3 t细胞接合抗体，在多种骨髓瘤模型中体外和体内抗肿瘤效果稳健地说明了稳健性，与BCMA汽车T细胞相当
2. Treatment with AMG 420, an Anti-B-Cell Maturation Antigen (BCMA) Bispecific T-Cell Engager (BiTE (R)) Antibody Construct, Induces Minimal Residual Disease (MRD) Negative Complete Responses in Relapsed and/or Refractory (R/R) Multiple Myeloma (MM) Patients: Results of a First-in-Human (FIH) Phase I Dose Escalation Study [J] . Topp Max S., Duell Johannes, Zugmaier Gerhard, Blood: The Journal of the American Society of Hematology . 2018,第NovaelaTreatmentAppr期

机译：用AMG 420处理，一种抗B细胞成熟抗原（BCMA）双特异性T细胞参录手（咬合（R））抗体构建体，诱导最小的残留疾病（MRD）在复发和/或难治度（R / R））多发性骨髓瘤（mm）患者：先进（FIH）I剂量升级研究的结果
3. A bispecific antibody-IFNalpha2b immunocytokine targeting CD20 and HLA-DR is highly toxic to human lymphoma and multiple myeloma cells. [J] . Rossi EA, Rossi DL, Stein R, Cancer research: The official organ of the American Association for Cancer Research, Inc . 2010,第19期

机译：靶向CD20和HLA-DR的双特异性抗体-IFNalpha2b免疫细胞因子对人淋巴瘤和多发性骨髓瘤细胞具有高度毒性。
4. Development of a Fully Human T-Cell Engaging Bispecific Antibody for the Treatment of Multiple Myeloma [C] . Duy T. Pham, Ben Buelow, Priya Choudry, Protein Engineering Summit. . 2018

机译：开发一种完全人体T细胞接合双特异性抗体治疗多发性骨髓瘤
5. Targeted Capture and Sequencing of Immunoglobulin Rearrangements in Multiple Myeloma to Enable Detection of Minimal Residual Disease [D] . Chow, Signy. 2017

机译：在多发性骨髓瘤中针对性捕获和免疫球蛋白重排测序，以检测出最小的残留疾病
6. I-BET151 suppresses osteoclast formation and inflammatory cytokines secretion by targetting BRD4 in multiple myeloma [O] . Ning-Hong Guo, Ji-Fu Zheng, Fu-Ming Zi, 2019

机译：I-BET151通过靶向多发性骨髓瘤中的BRD4抑制破骨细胞形成和炎性细胞因子的分泌
7. A Bispecific Antibody-IFNα2b Immunocytokine Targeting CD20 and HLA-DR Is Highly Toxic to Human Lymphoma and Multiple Myeloma Cells [O] . Edmund A. Rossi, Diane L. Rossi, Rhona Stein, 2010

机译：靶向CD20和HLA-DR的双特异性抗体-IFNα2B免疫键肽对人淋巴瘤和多发性骨髓瘤细胞具有高毒性

A Novel bispecific BCMAxCD3 T cell-engaging antibody that treat multiple myeloma (MM) with minimal cytokine secretion

著录项

引文网络

相似文献

相关主题

期刊订阅